{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:45:36Z","timestamp":1791413136527,"version":"4.3.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DF\/HCC Kidney Cancer SPORE","award":["P50CA101942"],"award-info":[{"award-number":["P50CA101942"]}]},{"name":"DF\/HCC Kidney Cancer SPORE","award":["P50CA101942"],"award-info":[{"award-number":["P50CA101942"]}]},{"name":"Claudia Adams Barr Program for Innovative Cancer Research"},{"name":"2014 AACR Basic Cancer Research Fellowship","award":["14-40-01-MAHO"],"award-info":[{"award-number":["14-40-01-MAHO"]}]},{"name":"2014 ASCO Young Investigator Award supported by Kidney Cancer Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00262-018-2282-1","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T04:51:09Z","timestamp":1545108669000},"page":"421-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-6803","authenticated-orcid":false,"given":"Kathleen M.","family":"Mahoney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2445-3584","authenticated-orcid":false,"given":"Sachet A.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8746-5692","authenticated-orcid":false,"given":"Nikolaos","family":"Patsoukis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8785-234X","authenticated-orcid":false,"given":"Apoorvi","family":"Chaudhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-7015","authenticated-orcid":false,"given":"Edward P.","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Arazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-3540","authenticated-orcid":false,"given":"Thomas M.","family":"Eisenhaure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William F.","family":"Pendergraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung C.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baogong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2349-2656","authenticated-orcid":false,"given":"Nir","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward F.","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3963-1518","authenticated-orcid":false,"given":"Vassiliki A.","family":"Boussiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-5054","authenticated-orcid":false,"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-5616","authenticated-orcid":false,"given":"Gordon J.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"issue":"Suppl 1","key":"2282_CR1","first-page":"82","volume":"4","author":"KM Mahoney","year":"2016","unstructured":"Mahoney KM et al (2016) A secreted PD-L1 splice variant expressed across tumor types inhibits lymphocyte function. J Immunother Cancer 4(Suppl 1):82 (Poster)","journal-title":"J Immunother Cancer"},{"key":"2282_CR2","doi-asserted-by":"crossref","unstructured":"Mahoney KM et al (2018) A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Kidney Cancer Symposium, November 3, 2018, Miami, Florida (oral presentation)","DOI":"10.1007\/s00262-018-2282-1"},{"issue":"7","key":"2282_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027\u20131034","journal-title":"J Exp Med"},{"issue":"7","key":"2282_CR4","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","volume":"66","author":"RH Thompson","year":"2006","unstructured":"Thompson RH et al (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7):3381\u20133385","journal-title":"Cancer Res"},{"key":"2282_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2016.03.002","volume":"59","author":"F Finkelmeier","year":"2016","unstructured":"Finkelmeier F et al (2016) High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer 59:152\u2013159","journal-title":"Eur J Cancer"},{"issue":"7","key":"2282_CR6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","volume":"17","author":"X Frigola","year":"2011","unstructured":"Frigola X et al (2011) Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res 17(7):1915\u20131923","journal-title":"Clin Cancer Res"},{"issue":"38","key":"2282_CR7","doi-asserted-by":"crossref","first-page":"41228","DOI":"10.18632\/oncotarget.5682","volume":"6","author":"L Wang","year":"2015","unstructured":"Wang L et al (2015) Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget 6(38):41228\u201341236","journal-title":"Oncotarget"},{"issue":"12","key":"2282_CR8","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/leu.2014.137","volume":"28","author":"D Rossille","year":"2014","unstructured":"Rossille D et al (2014) High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 28(12):2367\u20132375","journal-title":"Leukemia"},{"key":"2282_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2016.11.023","volume":"104","author":"Y Okuma","year":"2017","unstructured":"Okuma Y et al (2017) High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer 104:1\u20136","journal-title":"Lung Cancer"},{"issue":"57","key":"2282_CR10","doi-asserted-by":"publisher","first-page":"97671","DOI":"10.18632\/oncotarget.18311","volume":"8","author":"X Zhu","year":"2017","unstructured":"Zhu X, Lang J (2017) Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget 8(57):97671\u201397682","journal-title":"Oncotarget"},{"issue":"23","key":"2282_CR11","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.18632\/oncotarget.2608","volume":"5","author":"W Fang","year":"2014","unstructured":"Fang W et al (2014) EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 5(23):12189\u201312202","journal-title":"Oncotarget"},{"issue":"17","key":"2282_CR12","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268\u20133277","journal-title":"Blood"},{"issue":"7607","key":"2282_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K et al (2016) Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers. Nature 534(7607):402\u2013406","journal-title":"Nature"},{"issue":"127","key":"2282_CR14","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM et al (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4(127):127ra37","journal-title":"Sci Transl Med"},{"issue":"1\u20132","key":"2282_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.imlet.2011.11.001","volume":"142","author":"X Frigola","year":"2012","unstructured":"Frigola X et al (2012) Soluble B7-H1: differences in production between dendritic cells and T cells. Immunol Lett 142(1\u20132):78\u201382","journal-title":"Immunol Lett"},{"issue":"2","key":"2282_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.cyto.2011.06.004","volume":"56","author":"Y Chen","year":"2011","unstructured":"Chen Y et al (2011) Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1 + cell lines. Cytokine 56(2):231\u2013238","journal-title":"Cytokine"},{"issue":"6","key":"2282_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","volume":"5","author":"J Zhou","year":"2017","unstructured":"Zhou J et al (2017) Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res 5(6):480\u2013492","journal-title":"Cancer Immunol Res"},{"key":"2282_CR18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3389\/fphar.2018.00536","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y et al (2018) Regulation of PD-L1: emerging routes for targeting tumor immune evasion. Front Pharmacol 9:536","journal-title":"Front Pharmacol"},{"issue":"34","key":"2282_CR19","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1038\/s41388-018-0303-3","volume":"37","author":"I Zerdes","year":"2018","unstructured":"Zerdes I et al (2018) Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene 37(34):4639\u20134661","journal-title":"Oncogene"},{"issue":"51","key":"2282_CR20","doi-asserted-by":"publisher","first-page":"88360","DOI":"10.18632\/oncotarget.21729","volume":"8","author":"Z Liang","year":"2017","unstructured":"Liang Z et al (2017) High-affinity human PD-L1 variants attenuate the suppression of T cell activation. Oncotarget 8(51):88360\u201388375","journal-title":"Oncotarget"},{"issue":"4","key":"2282_CR21","doi-asserted-by":"publisher","first-page":"834","DOI":"10.2144\/99274rr06","volume":"27","author":"B Zhumabayeva","year":"1999","unstructured":"Zhumabayeva B, Chenchik A, Siebert PD (1999) RecA-mediated affinity capture: a method for full-length cDNA cloning. Biotechniques 27(4):834\u2013836 (838, 840 passim)","journal-title":"Biotechniques"},{"issue":"3","key":"2282_CR22","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","volume":"170","author":"JA Brown","year":"2003","unstructured":"Brown JA et al (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170(3):1257\u20131266","journal-title":"J Immunol"},{"key":"2282_CR23","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/2326-6066.CIR-15-0116","volume":"3","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM et al (2015) PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Cancer Immunol Res 3:1308\u20131315","journal-title":"Cancer Immunol Res"},{"key":"2282_CR24","doi-asserted-by":"publisher","first-page":"aad8366","DOI":"10.1126\/science.aad8366","volume":"350","author":"EM Allen Van","year":"2015","unstructured":"Van Allen EM et al (2015), Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science 350:aad8366","journal-title":"Science"},{"issue":"1","key":"2282_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W et al (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165(1):35\u201344","journal-title":"Cell"},{"issue":"3","key":"2282_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2144\/000112536","volume":"43","author":"B Zhu","year":"2007","unstructured":"Zhu B et al (2007) In-fusion assembly: seamless engineering of multidomain fusion proteins, modular vectors, and mutations. Biotechniques 43(3):354\u2013359","journal-title":"Biotechniques"},{"key":"2282_CR27","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis N et al (2015) PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 6:6692","journal-title":"Nat Commun"},{"issue":"3","key":"2282_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261\u2013268","journal-title":"Nat Immunol"},{"issue":"4","key":"2282_CR29","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","volume":"214","author":"VR Juneja","year":"2017","unstructured":"Juneja VR et al (2017) PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med 214(4):895\u2013904","journal-title":"J Exp Med"},{"issue":"3","key":"2282_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18(3):153\u2013167","journal-title":"Nat Rev Immunol"},{"issue":"19","key":"2282_CR31","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833","journal-title":"N Engl J Med"},{"issue":"19","key":"2282_CR32","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813","journal-title":"N Engl J Med"},{"issue":"5","key":"2282_CR33","doi-asserted-by":"publisher","first-page":"e1310358","DOI":"10.1080\/2162402X.2017.1310358","volume":"6","author":"S Kruger","year":"2017","unstructured":"Kruger S et al (2017) Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology 6(5):e1310358","journal-title":"Oncoimmunology"},{"issue":"2","key":"2282_CR34","doi-asserted-by":"publisher","first-page":"e12795","DOI":"10.1111\/aji.12795","volume":"79","author":"EAL Enninga","year":"2018","unstructured":"Enninga EAL et al (2018) Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy. Am J Reprod Immunol 79(2):e12795","journal-title":"Am J Reprod Immunol"},{"issue":"2","key":"2282_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/sji.12564","volume":"86","author":"Y Chen","year":"2017","unstructured":"Chen Y et al (2017) sPD-L1 expression is associated with immunosuppression and infectious complications in patients with acute pancreatitis. Scand J Immunol 86(2):100\u2013106","journal-title":"Scand J Immunol"},{"issue":"13","key":"2282_CR36","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"Chen BJ et al (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19(13):3462\u20133473","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2282-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2282-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2282-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T02:09:36Z","timestamp":1605665376000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2282-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2282"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2282-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"25 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shukla has equity in 152 Therapeutics. Freeman and Boussiotis have patents\/pending royalties on the PD-1 pathway from Bristol-Myers-Squibb, Roche, Merck, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Dako, and Novartis. Freeman has a patent application for the use of 9A11 antibody for diagnostic purposes. Hacohen and Wu are founders of Neon Therapeutics and members of its scientific advisory board. Patent applications have been filed: Compositions and Methods for Personalized Neoplasia Vaccines (Hacohen, Fritsch, and Wu), Methods for Identifying Tumor Specific Neo-Antigens (Hacohen and Wu), and Combination Therapy for Neoantigen Vaccine (Hacohen, Wu, and Fritsch). Fritsch is a co-founder and employee of Neon Therapeutics, Inc. All other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol (#13-3774) for the sequencing of sorted peripheral blood cells from normal healthy donors was passed by the University of North Carolina\u2019s Internal Review Board; donors signed informed consent. The protocol #93-011, (B7 Costimulation Protocol (The Role of PD-1 Ligand in Immune Evasion by Breast Cancer)) for the use for collection of blood from healthy donors was passed by the Dana-Farber\/Harvard Cancer Center\u2019s Internal Review Board for the use in lymphocyte activation assays; informed consent was waived as donors are anonymous and cannot be identified.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards\/informed consent"}},{"value":"HDLM2, L428, OC1-LY1 hematologic cell lines were a gift of Dr. Margaret Shipp []. Kidney cancer cell lines (Caki-2, 769-P, SN12C, UMRC6) were a gift of Drs. Chuan Shen and William Kaelin. MDA-MB-231, SKBR3, and BT474 were obtained from American Type Culture Collection (ATCC). Adherent epithelial cell lines (renal and breast lines) were passed by trypsinization; for flow cytometry, adherent cells were detached from plastic with 1\u00a0mM EDTA-PBS to minimize cleavage of extracellular protein domains for authentification by cell-surface markers. Lymphoid and kidney cell lines were authenticated by expression of cell-surface lineage markers. Cell lines from ATCC were authenticated at ATCC by STR profiling and maintained in culture for less than 6 months.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}